Amylyx Pharmaceuticals Etf Filter Stocks by Fundamentals
| AMLX Etf | USD 5.53 0.00 0.00% |
Amylyx Pharmaceuticals fundamentals help investors to digest information that contributes to Amylyx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Amylyx Etf. The fundamental analysis module provides a way to measure Amylyx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amylyx Pharmaceuticals etf.
Amylyx |
Amylyx Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Amylyx Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amylyx Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amylyx Pharmaceuticals' value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.8 M | Millennium Management Llc | 2024-06-30 | 1.5 M | Nantahala Capital Management, Llc | 2024-09-30 | 1.4 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.2 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.2 M | Qube Research & Technologies | 2024-06-30 | 789.1 K | D. E. Shaw & Co Lp | 2024-09-30 | 691.1 K | Alpha Wave Global Lp | 2024-09-30 | 669.5 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 621.9 K | Tcg Crossover Management, Llc | 2024-09-30 | 4.6 M | Aqr Capital Management Llc | 2024-06-30 | 3.3 M |
Fund Asset Allocation for Amylyx Pharmaceuticals
The fund invests 50.03% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Amylyx Pharmaceuticals' investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Amylyx Fundamentals
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.43 | ||||
| Profit Margin | (1.32) % | ||||
| Operating Margin | (181.88) % | ||||
| Current Valuation | 161.64 M | ||||
| Shares Outstanding | 68.55 M | ||||
| Shares Owned By Insiders | 14.32 % | ||||
| Shares Owned By Institutions | 82.46 % | ||||
| Number Of Shares Shorted | 1.53 M | ||||
| Price To Book | 2.01 X | ||||
| Price To Sales | 2.00 X | ||||
| Revenue | 380.79 M | ||||
| Gross Profit | (74.21 M) | ||||
| EBITDA | 39.89 M | ||||
| Net Income | 49.27 M | ||||
| Cash And Equivalents | 206.68 M | ||||
| Cash Per Share | 3.53 X | ||||
| Total Debt | 4.24 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.96 X | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | 11.92 M | ||||
| Short Ratio | 0.82 X | ||||
| Earnings Per Share | (3.82) X | ||||
| Price To Earnings To Growth | (0.15) X | ||||
| Target Price | 7.5 | ||||
| Number Of Employees | 384 | ||||
| Beta | -0.7 | ||||
| Market Capitalization | 393.46 M | ||||
| Total Asset | 517.45 M | ||||
| Retained Earnings | (304.95 M) | ||||
| Working Capital | 382.62 M | ||||
| Net Asset | 517.45 M | ||||
| Equity Positions Weight | 50.03 % |
About Amylyx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amylyx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amylyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amylyx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.